Genkyotex S.A.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Genkyotex S.A. - overview
Established
2006
Location
-, -, France
Primary Industry
Biotechnology
About
Genkyotex S. A. is a biotechnology company specializing in the development of innovative therapeutic solutions, focusing on NOX inhibitor technologies for treating fibrotic and inflammatory diseases. Founded in 2006 in France, Genkyotex S.
A. focuses on developing therapies based on its NOX inhibitor platform. The company was acquired by Calliditas Therapeutics AB in November 2020, when they purchased 62. 7% of Genkyotex for EUR 19.
75 million. Genkyotex operates from its headquarters in France, leveraging the expertise of its founder, who has a background in biotechnology. Genkyotex S. A.
and its subsidiary, Genkyotex Suisse S. A. , develop therapeutic solutions centered on their NOX inhibitor platform, particularly their lead product, setanaxib. This platform targets NAPH oxidase (NOX) enzymes involved in fibrotic and inflammatory diseases.
The company's primary customers are healthcare providers, research institutions, and pharmaceutical companies, with a focus on North America and Europe, addressing conditions like chronic liver diseases and certain cancers. In 2023, Genkyotex reported a revenue of EUR 1,026,135. 10 with an EBITDA of EUR -1,642,776. 50, reflecting its strategic partnerships and collaborations with larger pharmaceutical firms for product development and commercialization.
Genkyotex aims to expand its product offerings, with plans to launch new products based on its NOX inhibitor technology targeting additional fibrotic conditions. The company intends to further penetrate markets in North America and Europe, utilizing recent funding from the EUR 19. 75 million acquisition by Calliditas Therapeutics AB to support these initiatives. This funding will enhance their capabilities in research and development and facilitate market expansion efforts.
Current Investors
Andera Partners, Vesalius Biocapital, BioMed Partners
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.genkyotex.com
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Genkyotex S.A. - timeline of key events
Genkyotex S.A. - financials
| Fiscal Year Ended | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Mar 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - | 3,867,324 | 843,156 | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - | (78.2%) | - | - | - |
| EBITDA (USD) | (7,338,403) | (24,997,000) | (9,839,000) | (6,711,000) | (7,577,000) | (6,587,740) | (770,356) | - | - | - |
| Operating Income (USD) | (7,410,971) | (25,512,000) | (10,430,000) | (7,425,000) | (14,055,000) | (6,593,277) | (1,682,035) | - | - | - |
| Operating Margin | - | - | - | - | - | (170.5%) | (199.5%) | - | - | - |
| % EBITDA Margin | - | - | - | - | - | (170.3%) | (91.4%) | - | - | - |
| NET Income (USD) | (7,240,271) | (25,773,000) | (11,417,000) | (7,203,000) | (14,060,000) | 4,075,034 | 139,884 | - | - | - |
| % Net Margin | - | - | - | - | - | 105.4% | 16.6% | - | - | - |
Genkyotex S.A. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.